The global tuberculosis diagnostics market size was valued at USD 2.85 billion in 2023 and is anticipated to reach around USD 5.10 billion by 2033, growing at a CAGR of 5.99% from 2024 to 2033.
Tuberculosis (TB) remains one of the most persistent and devastating infectious diseases globally, despite decades of medical advancement and public health initiatives. The tuberculosis diagnostics market plays a crucial role in the detection, monitoring, and management of this disease, particularly in regions where the burden of TB remains high. Diagnostic tools range from conventional skin tests to sophisticated molecular diagnostics that identify drug-resistant strains and latent infections with increasing accuracy and speed.
Globally, over 10 million new TB cases are diagnosed annually, and with the resurgence of drug-resistant forms such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the need for accurate and timely diagnostics has become more pressing than ever. The World Health Organization (WHO) and national health agencies have emphasized the importance of early and reliable diagnostics to support disease surveillance, enable targeted treatment, and reduce TB-related mortality.
The global TB diagnostics market is influenced by a complex array of factors including government programs, international funding (such as from the Global Fund and USAID), emerging technologies, diagnostic automation, rising healthcare awareness, and evolving regulatory frameworks. Public-private partnerships, along with non-governmental efforts to provide cost-effective, point-of-care (POC) solutions, are significantly shaping the competitive dynamics of the market.
Shift Toward Molecular Diagnostics: Technologies such as nucleic acid amplification tests (NAATs), including GeneXpert and Truenat, are replacing traditional sputum smear microscopy.
Rise of Point-of-Care Testing (POCT): Portable TB diagnostic tools are being deployed in resource-limited settings to increase accessibility and reduce time to diagnosis.
Integration of AI and Digital Tools: AI-powered radiographic analysis and digital platforms for TB image interpretation are becoming more prominent, especially in developing countries.
Increased Focus on Drug Resistance Detection: Advanced molecular tests are being developed to detect resistance to both first-line and second-line TB drugs in a single test.
Collaborative Public-Private Partnerships: Governments and global organizations are investing in partnerships to scale up diagnostics availability, especially in high-burden countries.
Latent TB Infection Testing (LTBI): Growing emphasis on detection of LTBI, especially in immunocompromised populations (HIV/AIDS patients, organ transplant recipients).
WHO End TB Strategy Support: The market is aligning with the WHO goal of a 90% reduction in TB deaths and an 80% reduction in TB incidence by 2030.
| Report Attribute | Details |
| Market Size in 2024 | USD 3.02 Billion |
| Market Size by 2033 | USD 5.10 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 5.99% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Test type, end use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Abbott, QIAGEN, Thermo Fisher Scientific Inc., BD, F. Hoffmann-La Roche AG, Hologic, Inc., Cepheid, DiaSorin S.p.A., Hain Lifescience GmbH, Oxford Immunotec |
The most significant driver of the TB diagnostics market is the persistent global burden of tuberculosis, particularly in low- and middle-income countries. According to WHO estimates, TB is the 13th leading cause of death worldwide and the second leading cause from a single infectious agent, after COVID-19. The rise of drug-resistant TB (DR-TB) has compounded the challenge, as traditional treatment and diagnosis methods are often ineffective.
MDR-TB and XDR-TB require more advanced diagnostics capable of identifying specific resistance patterns. The demand for rapid, sensitive, and scalable molecular diagnostics has led to increased adoption of PCR-based tests and automated NAAT platforms. Governments and health organizations are also focusing on strengthening laboratory capacity, supporting the expansion of TB diagnostic networks.
In response, companies like Cepheid (Danaher) have expanded their offerings with cartridge-based systems like GeneXpert MTB/RIF Ultra, which detect both TB and rifampicin resistance. The growing urgency to curb disease transmission, reduce mortality, and meet WHO goals ensures continued investment and innovation in diagnostics.
While advanced molecular diagnostic tools offer higher accuracy and speed, their high cost remains a major barrier, particularly in resource-constrained settings. PCR-based systems and line probe assays can cost significantly more than conventional microscopy or skin tests, not just in equipment but also in reagents, maintenance, and training.
This cost disparity restricts widespread adoption in many developing countries, where TB prevalence is often highest. Additionally, the infrastructure requirements (such as reliable electricity, trained personnel, and controlled lab conditions) associated with sophisticated diagnostic platforms create hurdles for rural and remote deployments.
Although global health agencies and governments often subsidize these technologies, the dependence on external funding and limited local manufacturing capabilities can lead to operational disruptions. This financial barrier hinders equitable access to cutting-edge TB diagnostics across the most vulnerable populations.
A growing opportunity in the TB diagnostics market lies in the expansion of decentralized and point-of-care (POC) testing, particularly in underserved regions. Traditional diagnostic workflows often require multiple patient visits and lengthy turnaround times, which can result in delayed treatment initiation and poor outcomes.
Innovations in portable, battery-operated devices are enabling rapid molecular testing outside central laboratories. Platforms like Molbio’s Truenat (India) and Abbott’s ID NOW are gaining traction for their ability to deliver NAAT-based results in less than an hour. These systems are revolutionizing diagnosis in primary care clinics, mobile health units, and even rural dispensaries.
Moreover, smartphone integration, cloud-based reporting, and simplified user interfaces are allowing less-trained personnel to operate these tests with minimal error. Expansion of such solutions, supported by strategic public-private partnerships and international aid, can dramatically improve diagnostic coverage and accelerate TB control.
Nucleic Acid Testing (NAT) dominates the TB diagnostics market, primarily due to its high sensitivity, specificity, and ability to detect drug resistance. Automated platforms such as Cepheid’s GeneXpert and Molbio’s Truenat are widely used in national TB programs and by global health organizations. These tests allow for simultaneous detection of TB and rifampicin resistance, offering results within 1–2 hours. NAT has become the gold standard in many high-burden countries and is favored for its integration into lab-based and point-of-care settings.
Detection of Drug Resistance is the fastest-growing segment, reflecting the increasing need for personalized treatment in response to rising DR-TB cases. Tests like line probe assays (LPAs) and next-generation sequencing (NGS) are increasingly being used to identify mutations associated with resistance to first-line (e.g., isoniazid, rifampicin) and second-line drugs. Companies like Hologic and Thermo Fisher are developing multiplex assays that offer expanded resistance panels. The speed and comprehensiveness of these tests are essential for timely therapeutic intervention, reducing disease progression and transmission.
Hospitals and Clinics dominate the end-use segment, accounting for the largest share of TB diagnostics consumption. These facilities serve as the primary point of contact for symptomatic patients and often manage both inpatient and outpatient care. Hospitals are increasingly equipped with in-house laboratories and receive funding from national programs to operate advanced diagnostic tools. In countries with government-sponsored TB control efforts, clinics are integrated with diagnostic units that provide direct sputum testing, skin testing, and molecular assays.
Diagnostic Laboratories are the fastest-growing segment, propelled by rising sample outsourcing, centralized testing models, and private sector participation. In urban centers, independent labs and diagnostic chains are investing in high-throughput platforms to offer TB testing as part of broader infectious disease panels. The growth of home sample collection, online consultation platforms, and telemedicine is further boosting this segment, making TB testing more accessible and scalable.
Asia-Pacific leads the global TB diagnostics market, accounting for the highest disease burden and diagnosis volume. Countries like India, China, Indonesia, and the Philippines collectively represent over 50% of global TB cases. National TB programs in these countries have adopted innovative approaches, such as deploying GeneXpert and Truenat in peripheral centers and linking patients via digital notification systems.
India’s National Tuberculosis Elimination Program (NTEP), for instance, is among the world’s largest public health efforts, targeting TB elimination by 2025. The region also benefits from strong domestic manufacturing capabilities, public-private collaborations, and government support for diagnostic scaling.
Fastest Growing Region: Middle East & Africa (MEA)
The Middle East & Africa region is the fastest-growing TB diagnostics market, due to a combination of increasing investment, international aid, and heightened TB surveillance. Countries like South Africa face dual epidemics of TB and HIV, which has intensified diagnostic demand. WHO and the Global Fund have prioritized resource allocation to expand TB diagnostic access in sub-Saharan Africa.
Mobile testing labs, rapid molecular tools, and digitized patient tracking systems are being deployed to improve coverage. New partnerships between governments, NGOs, and diagnostic firms are facilitating equipment deployment, staff training, and long-term sustainability planning.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Tuberculosis Diagnostics market.
By Type
By End Use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers